Omalizumab治疗季节性过敏性鼻炎研究小组的Thomas B.Casale医师和他的同事们写道:「Omalizumab可以降低季节性过敏性鼻炎患者,血清游离的IgE抗体浓度,并可以根据药物剂量的不同,得到不同的临床疗效。」




  与对照组的患者相比,接受300mg,Omalizuma治疗的患者,鼻炎症状严重程度得分要显著降低。血清IgE抗体的浓度与鼻炎症状,和抗组胺药物的使用量呈显著的相关。虽然在过敏症好发的季节,接受300mg Omalizuma治疗的患者,的鼻炎特异的生活质量评分要比低剂量组,或对照组的得分要高,但服药后的副作用,在各组之间相似。

  作者写道: 「需要进行类似的试验,以便得到对季节性过敏性鼻炎患者,给予准确的临床用药剂量后治疗效果的全部资料。」

Omalizumab Effective in Seasonal Allergic Rhinitis

Decreases Symptoms, Serum IgE Levels

By Laurie Barclay, MD
WebMD Medical News

Reviewed by Dominique Walton Brooks, MD, MBA

Dec. 20, 2001 -- Omalizumab is effective against seasonal allergic rhinitis, according to a study reported in the Dec. 19 issue of The Journal of the American Medical Association.

"Omalizumab decreased serum free IgE levels and provided clinical benefit in a dose-dependent fashion in patients with seasonal allergic rhinitis," write Thomas B. Casale, MD, and colleagues from the Omalizumab Seasonal Allergic Rhinitis Trial Group.

Omalizumab is a recombinant, humanized, monoclonal anti-IgE antibody that forms complexes with free IgE, blocking its interaction with mast cells and basophils and lowering free-circulating IgE levels.

This randomized, double-blind, dose-ranging, placebo-controlled trial from July 25 through Nov. 21, 1997, involved 536 patients, aged 12 to 75, at 25 U.S. outpatient centers. Subjects had at least a two-year history of moderate to severe ragweed-induced seasonal allergic rhinitis and a baseline IgE level between 30 and 700 IU/mL.

Patients received placebo or omalizumab, 50 mg, 150 mg, or 300 mg subcutaneously immediately before ragweed season. During the pollen season, patients with baseline IgE levels of 151 to 700 IU/mL had treatment repeated every three weeks (four total treatments), and those with baseline IgE levels of 30 to 150 IU/mL had treatment repeated every four weeks (three total treatments).

Relative to patients on placebo, those on 300 mg of omalizumab had significantly lower nasal symptom severity scores. IgE reduction was significantly correlated with nasal symptoms and rescue antihistamine use. Throughout the allergy season, rhinitis-specific quality-of-life scores were better in patients on 300 mg of omalizumab than in those on lower dosages or placebo. Adverse event frequency was similar in all groups.

"Comparative trials will be necessary to define the exact placement of this agent in the therapeutic armamentarium for seasonal allergic rhinitis," the authors write.

© 2001 WebMD Corporation. All rights reserved.

2016/9/9 上午 11:22:00
2016/1/22 上午 10:50:10
2014/3/17 上午 10:57:44

   1   2   3   4   5   6   7   8   9   10